TY  - JOUR
AU  - Pouyiourou, Maria
AU  - Kraft, Bianca
AU  - Wohlfromm, Timothy
AU  - Stahl, Michael
AU  - Kubuschok, Boris
AU  - Löffler, Harald
AU  - Hacker, Ulrich T
AU  - Hübner, Gerdt
AU  - Weiss, Lena
AU  - Bitzer, Michael
AU  - Ernst, Thomas
AU  - Schütt, Philipp
AU  - Hielscher, Thomas
AU  - Delorme, Stefan
AU  - Kirchner, Martina
AU  - Kazdal, Daniel
AU  - Ball, Markus
AU  - Kluck, Klaus
AU  - Stenzinger, Albrecht
AU  - Bochtler, Tilmann
AU  - Krämer, Alwin
TI  - Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial.
JO  - Nature Communications
VL  - 14
IS  - 1
SN  - 2041-1723
CY  - [London]
PB  - Nature Publishing Group UK
M1  - DKFZ-2023-02165
SP  - 6761
PY  - 2023
N1  - #EA:A360#LA:A360#
AB  - Cancer of unknown primary has a dismal prognosis, especially following failure of platinum-based chemotherapy. 10-20
LB  - PUB:(DE-HGF)16
C6  - pmid:37875494
DO  - DOI:10.1038/s41467-023-42400-5
UR  - https://inrepo02.dkfz.de/record/284981
ER  -